Posts Tagged ‘pharma’

Piramal group launches project to fight chronic diseases

August 17th, 2008

Mumbai (PTI): Aiming to provide affordable medicines in rural areas and to combat chronic diseases in the country, Pharma major Piramal Group in collaboration with ASSOCHAM and various NGOs launched a project here on Saturday.

The Programme ‘help-your-body’, inaugurated by former President APJ Abdul Kalam, will emphasis on imparting knowledge on healthy food for healthy body and target each and every individual.

“Genetic causes, obesity, stress, inappropriate dietary habits and lack of exercise play a major role in causing chronic ailments,” Swati Piramal, Piramal Group’s Director said.

According to a WHO report, 38.8 core people will die in the next ten years due to chronic diseases and a significant proportion would be from India.

“India is expected to be the chronic disease capital with over 70 million diabetics, 213 million hypertensive patients and 60 million with arthritis by 2025. We feel the government, the private sector, the medical fraternity, NGOs should come together against the onslaught of chronic diseases,” Piramal said.

Kalam suggested that the group should integrate various systems of medicine such as Allopathy, Ayurveda, homeopathy, Unani, Siddha and yoga available in the country to fight chronic ailments at an affordable cost.
» Read more: Piramal group launches project to fight chronic diseases

Dabur to hive off R&D subsidiary

August 15th, 2008

Dabur Research Foundation (DRF), the 29-year-old, not-for-profit organization that spearheads the research activities of the Dabur group, may soon become a standalone drug discovery firm to undertake international collaborative research programmes for the development of patented medicines. The bifurcation move comes close on the heels of the sale of Dabur Pharma to German healthcare major Fresenius SE.

“All DRF scientists engaged in generic (off-patent) oncology drug development business have been shifted to Dabur Pharma. DRF will now focus purely on drug discovery programmes,” DRF Chairman Anand Burman said. He declined to divulge the details of the ongoing collaborative research programmes due to confidentiality clauses, but hinted that at least one research is in the area of oncology.

According to him, continuing drug research, even after selling off their drug company, makes sense as DRF has been fashioned as an independent research entity.

While over 100 scientists moved out of DRF to be part of the research team of Dabur Pharma, majority of other scientists conducting research in areas like Ayurveda, Phytopharma, biotechnology, personal care products and food were shifted from DRF to Dabur India’s in-house research wing. DRF is now left with its drug discovery scientists and pursues at least three drug discovery programmes in collaboration with foreign universities and companies.

Though the Dabur Pharma website lists out the contract research services offered by DRF, Burman said the promoters are yet to take a final view on the future research programmes of DRF.

Fresenius, which closed Dabur acquisition on August 11, has acquired the rights for all existing products that have come out of DRF. “All discoveries that have been commercialized have gone to Fresenius, besides the patented nanotechnology-based drug delivery system and the entire team of scientists engaged in generic drug discovery research at DRF. Fresenius will continue at the same location for a short period,” Burman said.